- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
Phase 1 study of Verastem’s FAK inhibitor, VS-6063, starts
6 January 2016 • Author: Victoria White
Washington University has initiated a Phase 1 dose-escalation study to evaluate Verastem’s Focal Adhesion Kinase (FAK) inhibitor VS-6063 in combination with Merck’s PD-1 inhibitor pembrolizumab and gemcitabine in patients with pancreatic cancer.
This Phase 1 clinical trial is anticipated to enrol approximately 50 patients and is being conducted at the Washington University School of Medicine’s Division of Oncology under the direction of Andrea Wang-Gillam, MD, PhD, Clinical Director of the Gastrointestinal Oncology Programme.
“As recently published in Cell, preclinical studies strongly suggest that the inhibition of focal adhesion kinase combined with checkpoint inhibition may potentiate a more significant tumour immune response leading to both tumour shrinkage and durable disease control,” said Dr Wang-Gillam. “This trial is primarily designed to evaluate the safety of the combination and may also provide a greater understanding of how FAK inhibition in combination with immunotherapies could improve outcomes for patients with pancreatic cancer, one of the most deadly of all cancer types.”
Study supported by growing body of research on FAK inhibition
This clinical study is supported by a growing body of preclinical research suggesting that FAK inhibition, when combined with PD-1 inhibitors, increases the anti-tumour activity of these immunotherapeutic agents. FAK inhibition has been shown to increase cytotoxic (CD8+) T cells in tumours, decrease T cell exhaustion, decrease immunosuppressive cell populations, enhance T cell killing of tumour cells, and create a generally more favourable tumour microenvironment, which allows for enhanced efficacy of immuno-oncology therapeutics.
In addition to other “cold” tumours like glioblastoma and prostate, pancreatic cancer is a tumour type in which immunotherapeutics have achieved limited clinical benefit, possibly due to the dense desmoplastic stroma and the presence of high numbers of immunosuppressive cells. Preclinical research has demonstrated that high stromal density prevents anti-cancer agents and T cells from entering pancreatic tumours thereby limiting efficacy. In addition, FAK inhibition has been shown to reduce stromal density and allow cytotoxic T cells to better penetrate the tumour and kill the cancer cells.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Lonza MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. Peak Scientific ReAgent Russell Finex Limited Sentronic GmbH Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited WITec GmbH Xylem Analytics YMC Europe GmbH Yusen Logistics